Review Paper on Signaling Pathways; Her2+ and ER+ discussed

[Hopeful]

This is a tad technical, but an interesting read: http://breast-cancer-research.com/co...df/bcr2361.pdf

Hopeful

[Rich66]

Yep..onco-alphabet soup.

This concluding statement resembled English:

Currently, monotherapies that target the receptor or ERK1/2 activity are predicted to be of limited value. Instead, combination therapies that target growth factor receptors, multiple signalling pathways and signalling targets point the way forward [83,84]; an example of this would be an EGFR/ErbB2 inhibitor plus a multi-signalling pathway inhibitor (for example, the Ras farensyltransferase inhibitor, which blocks ERK1/2 activation and mTor (mammalian target of rapamycin) signals (or a Src inhibitor [182]) plus a ‘full oestrogen antagonist’ (for example, fulvestrant)). Rapid development of successful strategies in this area is keenly awaited.